Is hrtx stock a buy or sell?
According to 9 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is 31.50, which is an increase of 222.42% from the latest price.
What is Heron Therapeutics'(hrtx) price potential for the next year?
Their forecasts range from $25.00 to $27.00. On average, they anticipate Heron Therapeutics' share price to reach $26.00 in the next year. This suggests a possible upside of 192.5% from the stock's current price.
Will Heron Therapeutics (hrtx) outperform the S&P 500 over the long term?
Vote “Outperform” if you believe HRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Heron Therapeutics does not currently pay a dividend. Heron Therapeutics does not have a long track record of dividend growth.
How did hrtx's Revenue perform in 2020?
It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycli... [Read more...] In 2020, HRTX's revenue was $88.64 million, a decrease of -39.28% compared to the previous year's $145.97 million.
Is HRTX stock a buy?
Heron Therapeutics Inc (NASDAQ:HRTX) The 6 analysts offering 12-month price forecasts for Heron Therapeutics Inc have a median target of 11.00, with a high estimate of 40.00 and a low estimate of 7.50. The median estimate represents a +263.64% increase from the last price of 3.03.
What is going on with Heron Therapeutics?
Heron Therapeutics (HRTX) Reports Q4 Loss, Lags Revenue Estimates. Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 8.47% and 20.93%, respectively, for the quarter ended December 2021.
Why is Heron Therapeutics stock going down?
What's the specific culprit behind this hefty sell-off? The lack of commercial momentum for Heron's non-opioid painkiller Zynrelef appears to be the biggest concern for shareholders today. Even though the drug was launched last July, it failed to bring in even $1 million in net revenue for the company in Q4 2021.
What happened to biotech stocks?
The SPDR S&P Biotech exchange-traded fund (ticker: XBI) fell 17.9% in April, bringing the total drop for 2022 to 34.1%. Over the past 12 months, the XBI is down 46%, while the S&P 500 is just down 1.2%. The pain remains focused on the small and mid-cap biotechs.
Should I buy or sell Heron Therapeutics stock right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are...
What is Heron Therapeutics' stock price forecast for 2022?
2 equities research analysts have issued 1 year price objectives for Heron Therapeutics' shares. Their forecasts range from $7.50 to $25.00. On ave...
How has Heron Therapeutics' stock price performed in 2022?
Heron Therapeutics' stock was trading at $9.13 at the start of the year. Since then, HRTX shares have decreased by 74.7% and is now trading at $2.3...
When is Heron Therapeutics' next earnings date?
Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Her...
How were Heron Therapeutics' earnings last quarter?
Heron Therapeutics, Inc. (NASDAQ:HRTX) posted its earnings results on Monday, May, 9th. The biotechnology company reported ($0.63) earnings per sha...
Who are Heron Therapeutics' key executives?
Heron Therapeutics' management team includes the following people: Dr. Barry D. Quart Pharm.D. , Chairman & CEO (Age 65, Pay $1.1M) Mr. John W....
Who are some of Heron Therapeutics' key competitors?
Some companies that are related to Heron Therapeutics include Syndax Pharmaceuticals (SNDX) , Kura Oncology (KURA) , Merus (MRUS) , FibroGen (F...
What other stocks do shareholders of Heron Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology...
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
When will Heron Therapeutics release its earnings?
How much does Heron Therapeutics make?
Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021. View our earnings forecast for Heron Therapeutics.
Signals & Forecast
How much money does Heron Therapeutics make? Heron Therapeutics has a market capitalization of $1.32 billion and generates $88.64 million in revenue each year . The biotechnology company earns $-227,280,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis.
Support, Risk & Stop-loss
There are few to no technical positive signals at the moment. The Heron Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Heron Therapeutics stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Insiders are very positive buying more shares than they are selling in Heron Therapeutics
Heron Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 100 trades there were 1.3 million shares bought and 74.04 thousand shares sold. The last trade was done 41 days ago by Quart Barry D who sold 16.12 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
About HRTX
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Analyst Forecast
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs.
News
According to 6 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is 31.50, which is an increase of 282.05% from the latest price.
